ROSWELL, Ga., Oct. 30, 2023 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced additional positive data from the pivotal Phase 3 open-label study of the investigational Copper 175 mm2 intra-uterine device (IUD). The data presented at three recent women's health scientific congresses provide further support for the investigational, next-generation, hormone-free IUD as exhibited in its pivotal phase 3 trial.
BRAINTREE, Mass., June 22, 2023 /PRNewswire/ -- Sebela Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted approval of SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults. SUFLAVE, a low-volume, safe and effective colonoscopy preparation – with a taste similar to a lemon-lime sports drink – was developed and will be marketed by Braintree Laboratories, a leader in gastroenterology and part of Sebela Pharmaceuticals.
ROSWELL, Ga., March 21, 2023 /PRNewswire/ -- Sebela Women's Health Inc, a part of Sebela Pharmaceuticals, will present findings from a post-hoc comparison of payer costs for hormonal and non-hormonal intrauterine devices (IUDs) during the Academy of Managed Care Pharmacy Congress, March 21-24, 2023, in San Antonio, TX. Seven years of U.S. commercial claims data were analyzed to improve estimates of long-term, real-world costs, with specific attention to costs related to IUD complications and device removals.
A biotech in the UK has out-licensed a C. difficile candidate to a US biotech for further clinical and commercialization efforts.
Sebela Pharmaceuticals Announces New Division Named Sebela Women's Health
BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader in gastroenterology and an affiliate of Sebela Pharmaceuticals, will be responsible for clinical development, registration, marketing, and sales in the United States and Canada. Tegoprazan, a novel potassium-competitive acid-blocker (P-CAB), is currently approved and marketed in several territories, including South Korea and China.
ROSWELL, Ga., Oct. 24, 2022 /PRNewswire/ -- Sebela Pharmaceuticals, a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women's health, today announced the appointment of Victor Parker to the position of Chief Commercial Officer. Mr. Parker has more than 25 years of pharmaceutical experience, having served in commercial leadership roles at Prometheus Laboratories, Exact Sciences and Abbvie/Abbott. Mr. Parker will be responsible for Sebela's overall commercial strategy and execution and will serve on Sebela's Executive Committee.
BRAINTREE, Mass., Oct. 19, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader in gastroenterology and an affiliate of Sebela Pharmaceuticals, will be responsible for clinical development, registration, marketing, and sales in the United States and Canada. Tegoprazan, a novel potassium-competitive acid-blocker (P-CAB), is currently approved and marketed in several territories, including South Korea and China.
ROSWELL, Ga., Jan. 5, 2021 /PRNewswire/ -- Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States.
BRAINTREE, Mass., Nov. 10, 2020 /PRNewswire/ -- Sebela Pharmaceuticals® today announces that the U.S. Food and Drug Administration (FDA) approved SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets. SUTAB, a sulfate-based tablet preparation for colonoscopy, was developed and will be marketed by Braintree Laboratories, the makers of SUPREP® Bowel Prep Kit (sodium sulfate, potassium sulfate and magnesium sulfate) Oral Solution—the market leader in branded colonoscopy preparations.1 SUTAB gives patients and physicians an alternative to liquid-based colonoscopy preparations. Braintree, a leader in gastroenterology, is part of Sebela Pharmaceuticals.